← Back
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets through biomolecules interaction and enzyme mimetic activities
Monatshefte für Chemie - Chemical Monthly (2019) 150:1059–1071
https://doi.org/10.1007/s00706-019-2357-5
ORIGINAL PAPER
Ruthenium(II) carbonyl complexes containing thiourea ligand:
Enhancing the biological assets through biomolecules interaction
and enzyme mimetic activities
Paranthaman Vijayan1 · Subbarayan Vijayapritha1 · Chidambaram Ruba1 · Periasamy Viswanathamurthi1 ·
Wolfgang Linert2
Received: 25 June 2018 / Accepted: 8 January 2019 / Published online: 20 May 2019
© The Author(s) 2019
Abstract
The ligand H
2L (N-(N,N-diethylaminothiocarbonyl)benzimidoylchloride-2-aminoacetophenone-N-methylthiosemicarbazone)
reacts with ruthenium(II) building blocks [RuHCl(CO)(EPh3)3] (E = P or As) to form new complexes [Ru(1,1-DT)(Cl2)(CO)(EPh3)2] (E = P or As; 1,1-DT = 1,1-diethylthiourea). The ligand H
2L in these reactions undergoes C=N bond break and coordinates through sulfur atom of C=S group. Analytical and spectral (IR, UV–Vis, NMR, ESI-MS) methods were used to characterize the compounds. A distorted octahedral geometry for complexes has been furnished by X-ray crystallography, which
confirmed the coordination mode of the ligand with metal precursor. The binding affinity and mode of binding of the complex
towards some important biomolecules such as calf thymus DNA and bovine serum albumin protein were determined using
absorption and emission spectra and found intercalative binding with calf thymus DNA and static interaction with bovine serum
albumin. The in vitro cytotoxic activity of complex was assessed using human cervical cancer (HeLa), human hepatocellular
carcinoma (HepG2), and normal Vero cells. Furthermore, the complex was found to possess significant enzyme mimic catalytic
activity in oxidation and hydrolysis reactions.
Graphical abstract
Keywords Thiourea · Ruthenium(II) complex · DNA/BSA binding · Enzyme kinetics
Introduction
* Periasamy Viswanathamurthi
viswanathamurthi@gmail.com
* Wolfgang Linert
wlinert@mail.zserv.tuwien.ac.at
1
Department of Chemistry, Periyar University, Salem, India
2
Institute of Applied Synthetic Chemistry, Vienna University
of Technology, Vienna, Austria
In recent years, attention has been given for metallic
drug–DNA interaction in inorganic pharmaceutical research.
Due to the tunable coordination properties of the inorganic
drugs, the interaction of transition metal complexes with
molecular target DNA is of interest for understanding their
cytotoxic activities [1–3]. These compounds can bind with
DNA duplex through non-covalent interactions, viz intercalation between the bases, surface groove-binding, and
13
Vol.:(0123456789)
1060
P. Vijayan et al.
electrostatic attraction with anionic sugar–phosphate backbones [4]. Based on the interaction of biomolecules and
metal complexes, search for new metal-based drugs for
cancer treatment has led to an increasing significance for
the cytotoxic properties of metal complexes and their mechanisms of action [5, 6]. One of the great accomplishments in
the domain of medicinal inorganic chemistry is the introduction of cis-diamminedichloroplatinum(II) (cis-platin) and
its successors in the treatment of cancer. However, few of
their severe side effects such as renal toxicity, neurotoxicity, myelosuppression, immunosuppression, severe nausea,
vomiting, and ototoxicity impelled inorganic chemists to
explore new anticancer drugs based on transition metal complexes [7]. Among the various transition metal complexes
scrutinized, the ruthenium complexes are the most favorable alternatives in this regard due to their ease of synthesis,
advanced chemical and air stability, solubility, rich redox
chemistry, structural diversity, and kinetic aspects akin to
platinum [8, 9]. Presently, few ruthenium complexes were
entered in clinical trials as anticancer agents [10].
On the other hand, over the past few decades, attention has been made to artificial enzymes, which mimic the
structural and functional aspects of naturally occurring
enzymes, for utilizing oxidation of organic substrates in
the arena of industrial and synthetic processes [11]. In this
direction, many catalysts having bio-mimicking activity
for various enzymes have been synthesized by chemists.
Such artificial enzymes have the same catalytic function,
but they are more stable, cost-efficient, and structurally
less complex than their natural counterparts. One of the
prominent natural catecholase enzymes, a less well-known
member of the type-III copper proteins that originate
in plant tissues and crustaceans, plays a key role in the
Scheme 1
13
oxidation of a wide range of o-diphenols (catechol) to the
corresponding o-quinones [12, 13], a process known as
catecholase activity. Similarly, hydrolytic reactions, i.e.,
hydrolysis of phosphodiester bond (phosphodiester cleavage), a process called phosphatase activity, also involves
enzyme catalysis. Many research groups are working
towards synthesis of enzymes with different materials
including metal complexes to imitate the biological functions of above natural enzymes. Recently, our group has
reported metal complexes with various ligands [14], which
mimic catecholase and phosphatase activities.
Generally, the nature of ligands and chelation decides
the properties of the metal complexes. Nowadays, interest is being given to develop thiourea-based ligands that
support highly reactive transition metal complexes. N,N[(Dialkylamino)(thiocarbonyl)]benzamidine has been
observed as a diverse selection of multifunctional thiourea
scaffolds that can support metal ions by providing a wide
variety of different steric and electronic environments [15,
16]. A new class of tridentate thiocarbanoylbenzamidines
containing an additional thiosemicarbazone moiety and their
rhenium complexes have been reported recently together
with the biological activity of the compounds [17].
Motivated on the above contemplations and with the
aim to study transition metal complex interaction on biomolecules, we have synthesized ruthenium(II) complexes
containing thiourea ligands (Scheme 1). The interaction
studies of ruthenium(II) complex have been performed on
selected biomolecules such as calf thymus DNA (CT-DNA)
and bovine serum albumin (BSA) to determine the binding
mode. The cytotoxic as well as enzyme mimic activities of
the complex were also done to understand the biological
reactivity preferences.
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets…
Results and discussion
Synthesis and characterization
The ligand H
2L was obtained by simple condensation
using our previously reported methodology [18] with
crystalline purity and sufficient yield to use without further purification for the complex synthesis. Successively,
ruthenium(II) complexes 1, 2 were synthesized in good
yields by the reaction of H
2L and stable prefabricated
ruthenium(II) precursors [RuHCl(CO)(EPh 3) 3)] (E = P
or As) in C H 3OH/CHCl 3 solvent mixture as shown in
Scheme 1. Interestingly, the ligand undergoes hydrolytic
C=N bond cleavage and coordinates monodentate mode
via sulfur of C=S group with ruthenium metal.
The new complexes are crystalline solids, non-hygroscopic, air-stable in solution and solid state at room temperature. The complexes were characterized satisfactorily
by analytical, spectral (IR, UV–Vis, NMR, and ESI-MS)
as well as single crystal X-ray crystallography studies.
Spectroscopic analysis
The typical IR bands of the new ruthenium(II) complexes
were compared with those of the free ligand to find the
coordination mode of ligand in complexes. The spectrum
of ligand shows three peaks in the range of 3236–3302/
cm due to νNH groups, whereas in the spectra of complexes the νNH peaks disappeared indicates deprotonation of these groups in ligand on complexation. However,
in complexes 1 and 2 a new broad band was observed
in the region at 3379–3381/cm specified to new N
H2
group formed due to C=N bond break in the benzamidine
ligands [19]. A sharp band appeared range at 820–843/cm
in the spectrum of ligand was assigned to ν C=S group
which shifted to lower wave number in complexes 1 and
2 upon complex formation. The shift of ν C=S by 20–30
unit in complexes indicates that the ligand is coordinated
to the ruthenium(II) center via the sulfur atom. In addition, the ruthenium(II) complexes show strong vibrations in the anticipated region conform the presence of
triphenylphosphine and triphenylarsine. The electronic
spectra of ligand and complexes show two–four bands in
the region 237–443 nm. The bands in the 237–272 nm
regions can be assigned to π → π* and n → π* transitions
[20]. The absorption maxima located in the 332–339 nm
range were assigned to S(pπ) → M(dπ) (M = Ru2+) LMCT
transition for complexes 1 and 2. Furthermore, a broad
band at 438–443 nm region in the spectra of complexes
have been assigned to d–d transition band of spin-paired
d6 species with a distorted octahedral structure.
1061
The 1H NMR spectrum of ligand H2L shows three different NH resonances at 8.10, 8.47, and 12.72 ppm. But in
1 and 2, the peaks for NH groups were completely disappeared and a new peak appeared around 8.17–8.21 ppm
for –NH 2 due to ligand C=N bond cleavage. The four
well separated multiplet resonances at 3.52–3.94 ppm
have been assigned to two methylene groups in ligand
and its complexes 1 and 2. Furthermore, appearance of
two triplet signals region at 1.15–1.62 ppm were assigned
to N(CH 2CH 3) 2 methyl groups in the spectra of ligand
and its complexes [21, 22]. In addition, signals for aromatic protons appear in the expected region. In the 13C
NMR spectrum of uncoordinated ligand H 2L, the C=N
and C=S signals appear around 149.36–155.41 and
187.08–189.61 ppm, respectively [23]. In the spectra of
Ru(II) complexes, the signals of the C=N carbon disappeared and C=S carbon signals shifted to upfield region
(169.19–171.69 ppm). These are consistent with the sulfur
donor coordination for complexes 1 and 2 and break of
C=N bond in benzamidine ligands. The carbonyl carbon
resonates at 203.01–204.12 ppm, was comparable with
the literature reports. In addition, peaks for CH2 and C
H3
carbon were observed region at 13.21–32.61 ppm. Furthermore, the aromatic carbons in the complexes exhibit
peaks in the region of 127.62–138.83 ppm. The 31P NMR
spectrum of complex 1 show a sharp singlet at 34.83 ppm
indicates the coordination of two magnetically equivalent
triphenylphosphine co ligands in trans position [24]. The
mass spectral analysis of complexes 1, 2 reveals a signal that corresponds to a molecular ion at m/z = 821.32,
909.22, respectively, which is assigned to [M−Cl]+ with
an experimental isotope pattern that matches the calculated values.
X‑ray crystallographic analysis
X-ray crystallographic analysis of 1 and 2 also confirms
the metal-induced hydrolytic C=N bond break in H2L and
formation of unpredicted complexes 1 and 2. The crystal
structure and parameters of complex 1 are similar to the
previous report of our group in which the ligand undergoes similar hydrolytic cleavage [25]. Hence, here we
discuss only the crystal structure of complex 2 in detail
(Figs. 1, 2; Table 1). Similar to complex 1, complex 2
also displays an octahedral geometry. The coordination
sites are filled up by a C=S sulfur atom, a carbonyl group,
two chlorine atom and two triphenylarsine trans to each
other. The ruthenium atom is in a distorted octahedral
environment with trans angles of [As(2)–Ru(1)–As(1)]
176.61(4)° and [Cl(1)–Ru(1)–S(1)] 168.64(8)°. The other
two axial sites are occupied by a carbonyl group and one
chlorine atom with Ru(1)–C(1) and Ru(1)–Cl(1) distance
of 1.803(10) and 2.573(2) Å. The carbonyl group trans to
13
1062
P. Vijayan et al.
Table 1 Crystal data and structure refinement for complex 2
2
Fig. 1 Perspective view (25% probability ellipsoids) of complex 2
with the atom numbering scheme. Phenyl rings showed as wire frame
Empirical formula
Formula weight
Temperature/K
Wavelength/Å
Crystal system
Space group
Unit cell dimensions
a/Å
b/Å
c/Å
α/°
β/°
γ/°
Volume/Å3
Z
Density (calcd)/Mg/M3
Absorption coefficient
F(000)
ɵ Range for data collection/°
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indices [I > 2σ(I)]
R indices (all data)
C42H42As2Cl2N2ORuS
944.64
293(2)
0.71073
Monoclinic
P 1 21/c 1
12.9337(7)
18.3880(8)
17.7344(7)
90
102.314(5)
90
4120.7(3)
4
1.523
2.189/mm
1904
3.313–29.434
− 17 ≪ h ≪ 17
− 18 ≪ k ≪ 25
− 23 ≪ l ≪ 18
22,883
9837 [R(int) = 0.0613]
9837/0/462
1.011
R1 = 0.0843,
wR2 = 0.2185
R1 = 0.1791, wR2 = 0.2882
DNA interaction studies
Fig. 2 Weak hydrogen bonding interactions between Cl and NH atom
in complex 2
the coordinated Cl(2) atom [Cl(2)–Ru(1)–C(1)] with an
angle of 176.3(3)°. This is due to strong Ru(II) → CO back
donation as showed by the short Ru(1) − C(1) [1.803(10)
Å] bond and low CO stretching frequency (1952/cm),
which prefers σ or π weak donor groups occupying the site
opposite to CO to favor the d–π back bonding donation.
The second chloride ion attached to the ruthenium ion can
be furnished by chloroform solvent [25]. The metal ligand
bond distances (Table 2) in the complex 2 agree well with
previous reports containing similar coordination environment [26]. Moreover, the complex 2 exhibited weak hydrogen bonding interactions between Cl and NH atom.
13
Fluorescence emissive titration
Coordination compound and DNA interaction is one of the
criterions for comprehending the molecular basis of therapeutic activity or advanced clinical trials. Generally, molecules/
complexes bind non-covalently (intercalation, groove-binding
and external electrostatic mode) with DNA. The metal ion,
ligands and geometry of the complexes affect the binding
efficiency [27]. As a basic testing method, emissive titration study is unanimously employed method to find out the
binding mode of metal complexes with DNA which usually
involves the changes in emissive intensity and wavelength.
Emissive titration experiments were done by aliquot addition of DNA to the test compound and observe the changes in
emission intensity. The intercalative mode of affinity between
metal complexes and DNA results in hypochromism with or
without red/blue shift; on the other hand, non-intercalative/
1063
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets…
Table 2 Selected bond lengths (Å) and bond angles (°) for complex 2
2
C(1)–Ru(1)
As(2)–Ru(1)
As(1)–Ru(1)
S(1)–Ru(1)
Cl(1)–Ru(1)
Cl(2)–Ru(1)
As(1)–Ru(1)–Cl(1)
As(2)–Ru(1)–As(1)
As(2)–Ru(1)–Cl(1)
Cl(2)–Ru(1)–As(1)
Cl(2)–Ru(1)–As(2)
Cl(2)–Ru(1)–Cl(1)
S(1)–Ru(1)–As(1)
S(1)–Ru(1)–As(2)
S(1)–Ru(1)–Cl(1)
S(1)–Ru(1)–Cl(2)
C(1)–Ru(1)–As(1)
C(1)–Ru(1)–As(2)
1.803(10)
2.4750(12)
2.4844(11)
2.4096(16)
2.573(2)
2.466(2)
87.34(5)
176.61(4)
91.54(5)
88.14(8)
88.66(8)
90.29(8)
89.56(8)
92.14(8)
168.64(8)
100.53(8)
91.4(4)
91.7(4)
electrostatic interaction causes hyperchromism [28]. The
fluorescence emission titration curves (Fig. 3) were used to
study the binding mode and propensity of complex 2 with
CT-DNA in Tris–HCl buffer (5 mM Tris–HCl/50 mM NaCl
buffer for pH = 7.2) at 25 °C. Upon increasing concentration of CT-DNA, the emission spectral bands of complex 2
at 323 nm exhibit hypochromism of about 21.23% with very
small slight red shifts of 0.5 nm. The marked decreases in the
fluorescence intensity indicate the intercalative binding mode
of complex 2 and DNA. The calculated binding constant (Kb)
value (Table 3) is comparable to similar type of previously
reported complex [25] and also supports the intercalative mode
Table 3 Fluorescence spectral parameters of ruthenium complexes
bound with CT-DNA
Complex
Kb
Ksv
Kapp
1a
2
3.98 × 104
1.06 × 106
1.19 × 104
3.80 × 104
6.30 × 105
1.97 × 105
a
Data referred from Ref. [25]
[29]. However, some more experiments require for proving the
binding mode.
Fluorescence quenching study
To gain support for the type of binding of the complex with
CT-DNA, the fluorescence quenching studies were performed
using metal complex as a quencher. Ethidium bromide (EB) is
commonly used as sensitive fluorescent and emits enhanced
emissive property in the presence of DNA [30]. From the
above info in mind, the quenching of EB bound DNA is calculated with the successive addition of metal complex 2. The
emission band at 686 nm for EB displays hypochromism up
to 15.52% with a small red shift from the initial fluorescence
intensity (Fig. 4). From this evidence, it is concluded that EB is
being released from EB-DNA compound due to the reduction
of the corresponding ruthenium complex. The quenching constant (Ksv) value was calculated using classical Stern–Volmer
equation according to the previous literature [31], which was
listed in Table 3. In addition, the following equation is used to
calculate the apparent DNA-binding constant (Kapp) values:
]
[
KEB [EB] = Kapp M50% ,
where KEB = 1.0 × 10−7/M is the DNA-binding constant of
EB, [EB] is the concentration of EB (7.5 μM) and [M50%]
Fig. 3 Emission titrations of complex 2 (25 µM) with CT-DNA (0–50 µM) and Scatchard plots of r/Cf vs r for complex 2
13
1064
P. Vijayan et al.
Fig. 4 Emission titrations of complex 2 (0–50 µM) with EB bound CT-DNA (7.5 µM) and Scatchard plots of I0/I vs [Q] for complex 2
Viscosity measurements
To clarify the binding mode of the Ru(II) complex with
DNA, the viscosity measurements were carried out on CTDNA by varying the concentration of added complex. The
experiment involves the measurement of the flow rate of
DNA solution through a capillary viscometer. For a small
molecule that binds by non-classical intercalation, causes
less pronounced or no change in the viscosity of DNA [32].
On the other hand, a classical intercalation mode into DNA
causes a significant increase in the viscosity of DNA solution due to increase in the overall DNA molecular length.
The plot of (η/η0)1/3 vs [complex]/[DNA] gives a measure
of the viscosity changes (Fig. 5). The obtained plot shows
increase in the relative viscosity, which clearly indicates
intercalate binding mode for complexes. Therefore, we can
conclude that the complex 2 binds to CT-DNA in the intercalate regions, which is in accordance with fluorescence
spectral results.
Protein binding studies
The emission studies have also been used to explore the
interaction of complex 2 with BSA. BSA (1 μM) was titrated
with various increasing concentrations of 2 (0–50 μM) in the
13
1.1
1.09
1.08
1.07
(η/η0)1/3
is the concentration of the compound used to obtain a 50%
reduction in fluorescence intensity of DNA pretreated with
EB. The Ksv and Kapp values are found to be comparable
with our previous reported ruthenium(II) complex [25]. The
results support the intercalative binding mode of complex 2
with DNA and the results are consistent with the previous
emissive titrations.
1.06
1.05
1.04
1.03
1.02
1.01
1
-0.01
0.01
0.03
0.05
0.07
0.09
0.11
0.13
r = [Compound] / [DNA]
Fig. 5 Relative viscosity (η/η0)1/3 of CT-DNA in Tris–HCl buffer
solution in the presence of complex 2 at increasing amounts
(r = 0–0.12)
wave length 290–430 nm (λex = 280 nm) and their emission
spectra recorded. The fluorescence spectrum of BSA exhibits a broad band with a maximum at ~ 340 nm. The outcome
of increasing concentration of 2 on the emission spectra of
BSA at room temperature is shown in Fig. 6a. The value
of Stern–Volmer constant (Kq) calculated from following
Stern–Volmer equation [33] is used to express the amount
of quenching. Quenching constant (Kq) was found from the
plot of log (I0 − I)/I vs log[Q] (Fig. 6a) which is much higher
than the molecular fluorescence diffusing constant as shown
in Table 4. The result reveals that the fluorescence quenching mechanism of the compound-BSA system will not be
dynamic quenching. It may be static quenching. However,
1065
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets…
Fig. 6 Emission titrations of complex 2 (0–50 μM) with BSA (1 μM)
and Stern–Volmer plots of (I0 − I)/I vs. [Q] and Scatchard plots of
log [(I0 − I)/I] vs. log [Q] for complex 2 (upper A). Absorbance spec-
this conclusion needs to be confirmed through other experiments. The binding constant Kb was calculated using the
Scatchard equation:
[
]
log (I0 − I)∕I = log Kb + n log [Q],
where Kb is the binding constant of the complex with BSA
and n is the number of binding sites. The binding constant
(Kb) has been obtained as per Fig. 6a and its value is given in
Table 4 along with n. The value of n indicates the availability
tra of the complex 2 with BSA [dashed red line—BSA alone; green
line—BSA + complex 2] (lower B)
Table 4 Quenching parameters of ruthenium complexes bound with
BSA
Complex
Ksv
Kq
Kbin
n
1a
2
1.18 × 105
3.62 × 104
1.18 × 1013
3.62 × 1012
1.03 × 1010
1.12 × 1010
2.0
1.3
a
Data referred from Ref. [25]
13
1066
P. Vijayan et al.
Table 5 In vitro cytotoxicity of ruthenium complexes in normal and
cancer cell lines
Complex
1c
2
Cis-platin
IC50/µg/cm3a
Vero
HeLa
HepG2
50.60 ± 0.85
55.12 ± 0.47
NDb
28.69 ± 1.18
20.16 ± 1.10
12.29 ± 1.27
33.65 ± 1.75
25.39 ± 0.83
11.78 ± 1.52
a
50% inhibitory concentration after exposure for 24 h in the MTT
assay
b
c
No data
Data referred from Ref. [25]
of one binding site in BSA for complex 2. The higher values of Kq and Kb signify a strong interaction between the
BSA proteins. The quenching parameters for complex 2
are comparable to similar type of previously reported complex [25]. Furthermore, the static quenching fluorescence
mechanism of the compound is proved by UV–Vis absorption spectral studies. Generally, quenching happens either
by dynamic or static ways. When the fluorophore and the
quencher come into contact during the transient existence
of the excited state, dynamic quenching occurs [34]. On
the other hand, static quenching represents to the formation of fluorophore–quencher compound in the ground state.
UV–Vis absorption spectra of BSA have been measured in
the absence and presence of 2. Figure 6b shows that addition
of 2 to a fixed concentration of BSA leads to an increase in
the absorbance of the BSA absorption peak at 280 nm with
a small blue shift for free BSA, indicating that the complex
2 interact with BSA by the static quenching which could be
attributed to the formation of the ground state complex as
reported earlier [35].
In vitro cytotoxicity assay
The ruthenium complex was evaluated for its cytotoxicity
vs a pair of human tumor cell lines such as human cervical
cancer (HeLa), human hepatocellular carcinoma (HepG2),
and normal Vero cells by means of a colorimetric assay
(MTT assay) that measures mitochondrial enzyme succinate dehydrogenase activity as an indication of cell viability.
Cis-platin was used as the reference compound to evaluate the cytotoxic activity. The results were analyzed by cell
viability curves and expressed with I C50 values of complex
2 in Table 5. The amount of cell proliferation significantly
decreases in various concentration ranges (10–100 µg/cm3)
on supplementation with complex, as observed within 24 h
of incubation with respective of above cell lines.
From IC50 values, the complex demonstrates notable
activity in human cervical cancer (HeLa), human hepatocellular carcinoma (HepG2) cell lines. However, the complex
13
Scheme 2
shows marginally less activity than cis-platin and comparable activity with previously reported ruthenium complexes
[10, 23, 25, 26]. It is noteworthy that the complex 2 is less
toxic towards the normal Vero cell line as is evident from
the IC50 values.
Enzyme mimicking studies
Catecholase activity
3,5-Di-tert-butylcatachol (3,5-DTBC) was used as substrate
to study the catecholase mimic activity of the complex 2.
Due to the presence of two bulky tert-butyl substituents, the
substrate shows a low quinine–catechol reduction potential
and hence effortless oxidation occurs to the corresponding
o-quinone (Scheme 2).
The stable oxidation product 3,5-di-tert-butylquinone
(3,5-DTBQ) displays a maximum emission at 390 nm.
Before proceeding to a thorough kinetic study, the complex
2 (1 × 10−4 M) were examined by addition of complex 2 to
a 100 equivalents DMF solution of 3,5-DTBC (1 × 10−2 M)
under oxygen atmosphere and the progress of the reaction
was monitored for every 15 min interval up to 2 h. Owing
to addition of the catecholic substrate, a new band (Fig. 7)
appeared at 434 nm and its intensity steadily increased may
be due to ligand to metal charge transfer band of the oxidized product 3,5-di-tert-butylbenzoquinone (3,5-DTBQ).
Therefore, the experiment obviously demonstrates that the
oxidation of 3,5-DTBC to 3,5-DTBQ was catalyzed by 2,
as it is well known that 3,5-DTBQ displays a maximum at
λemis = 434 nm in DMF. The catalytic performance exhibits
saturation kinetics based on the Michaelis–Menten model
appeared to be suitable under excess substrate conditions.
Plots of ki vs [3,5-DTBC] provided non-linear curve of
decreasing slope (Fig. 7) which are best designated kinetic
equation by our earlier report [25]. The Michaelis–Menten
constant (Km) and maximum initial rate (Vmax) were determined by linearization using Lineweaver–Burk plots (Fig. 7).
The turnover number values (Kcat) were obtained by dividing
the Vmax values by the concentration of the complex and all
these parameters are listed in Table 6. The results unambiguously demonstrate that the complex 2 is active towards the
oxidation of 3,5-DTBC. When compared to similar reported
complex, the activity of the present complex is slightly lower
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets…
1067
Fig. 7 Oxidation of 3,5-DTBC by complex 2 monitored by emission spectroscopy and Lineweaver–Burk plot for complex 2
Table 6 Kinetic parameters for catecholase and phosphatase activity
of ruthenium complexes
Catalyst
Km/M
Vmax/M m1
Kcat/h−1
1 (3,5-DTBC)a
1 (4-NPP)a
2 (3,5-DTBC)
2 (4-NPP)
9.88 × 10−1
4.26 × 10−3
3.74 × 10−3
5.69 × 10−4
2.85 × 10−2
1.01 × 10−3
1.58 × 10−3
1.23 × 10−4
988
85
374
569
a
Data referred from Ref. [25]
although it possesses appreciable catecholase mimic activity [25]. From all the data, it is concluded that the catalytic
oxidation follows the mechanism suggested by Chyn and
Urbach [36].
Phosphatase activity
Based on the promising catecholase activity result, the complex was further investigated for its phosphatase activity.
Phosphate esters play several important functions in biological systems such as information storage (DNA/RNA),
cellular signaling (cAMP), and energy transduction (ATP)
[11]. The phosphodiester bonds in these molecules are
extremely resistant towards hydrolysis because of the repulsion between the negatively charged backbone and potential nucleophiles. Since the compound 4-nitrophenyl phosphate disodium salt hexahydrate (4-NPP) ester is negatively
charged and under neutral conditions they are very resistant
to hydrolysis, was selected as substrate. The 4-NPP hydrolysis was monitored using complex 2 as catalyst by emissive
titrations (Fig. 8) on the time evolution of 4-NP in DMF at
λemis = 486 nm (λex = 435 nm) over 15 min break up to 2 h
with 40 equivalents of the substrate (Scheme 3).
The dependence of the initial rate on the concentration of
the substrate was monitored at the respective wavelength by
emission spectroscopy, which corresponds to the increase
in 4-nitrophenolate (4-NP) concentration (Fig. 8). The rate
vs concentration of substrate data were analyzed based on
Michaelis–Menten approach of enzymatic kinetics to get the
Lineweaver–Burk (double reciprocal) plot as well as the values of variety of kinetic parameters Vmax, Km and Kcat. Plot
of ki vs [4-NPP] gave non-linear curve of decreasing slope
which is best designated by the first-order kinetic equation.
The turnover number value (Kcat) was obtained by dividing the Vmax value by the concentration of the complex and
all the parameters are listed in Table 6. The results show that
the complex 2 owns superior activity and effectively catalyze
the hydrolysis with appreciable turnover rate [25]. Moreover,
the kinetic data reveal that the hydrolysis of 4-NPP followed
the mechanism described earlier [25].
Conclusions
In conclusion, the ruthenium complexes 1 and 2 bearing
thiourea ligand have been synthesized and characterized by
analytical, spectral, and single crystal X-ray crystallographic
techniques. The characteristic results reveal the C=N bond
cleavage in ligands and monodentate coordination via C=S
group with the ruthenium metal ion. The results of single
crystal XRD analysis of complexes confirm ligand cleavage, monodentate coordination mode and octahedral geometry. The binding properties of the ruthenium complex with
13
1068
P. Vijayan et al.
Fig. 8 Hydrolysis of 4-NPP by the complex 2 monitored by emission spectroscopy and Lineweaver–Burk plot for complex 2
Scheme 3
CT-DNA were evaluated by emissive titrations, fluorescence
quenching, viscosity measurements, and the results show
that the complex interacts with CT-DNA through intercalative mode. Furthermore, the complex BSA protein interactions were examined by UV–Vis and emissive titrations
reveal that complex has shown high binding affinity and acts
as static quencher. The in vitro cytotoxic study demonstrates
the substantial cytotoxicity of the complex. Moreover, the
complex was effectively used for aerial oxidation of catechol
and phosphate hydrolysis. On the basis of Michaelis–Menton approach of enzyme kinetics, the complex shows good
catalytic efficiency in catechol-oxidase functional mimic in
the conversion of 3,5-DTBC to 3,5-DTBQ and ester hydrolysis functional mimic in the hydrolysis of 4-NPP to 4-NP in
aerobic conditions.
Experimental
All chemicals were procured commercially and used as
received. Solvents were dried and distilled following the
literature procedures [37] and reactions carried out under
room temperature. Microanalyses were performed using an
apparatus designed by Technico Instuments, India. Vario EL
13
III CHNS analyzer was used for elemental analysis measurement. Bruker FT IR spectrophotometer equipped with an
ATR sampling accessory was employed for recording IR
spectra in the range 4000–450/cm. UV–Vis spectra were
recorded on Shimadzu UV-1650 PC spectrophotometer over
800–200 nm range. 1H, 13C, 31P NMR spectra were performed on a Bruker Ultra Shield using DMSO-d6 and CDCl3
as solvent. The chemical shifts are given in ppm relative to
SiMe4 and orthophosphoric acid. ESI-MS were recorded on
a Q-TOF micro™ mass spectrometer operating in ESI mode.
Buffer solutions were prepared using doubly distilled water.
Stock solution of complex (1 mM in DMSO) was stored
at 4 °C and used whenever required. Data were expressed
as the mean ± the standard deviation from three independent experiments. The ruthenium precursors [RuHCl(CO)
(EPh3)3] (E = As or P) and the ligand (N-(N,N-diethylaminothiocarbonyl)benzimidoylchloride-2-aminoacetophenoneN-methylthiosemicarbazone) (H2L) were prepared according
to literature methods [18, 38].
Synthesis of complexes 1 and 2
The metal complexes were prepared as per reported procedure with minor alteration [39]. [RuHCl(CO)(EPh3)3] (E = P
or As) (1 mmol) and the ligand H2L (1 mmol) were dissolved
in 10 cm3 of methanol and chloroform solvent mixture (1:1
ratio). The solution mixture was mildly heated under reflux
for 12 h. The progress of the reaction was monitored by thin
layer chromatography (TLC) using 9:1 mixture of petroleum
ether–ethyl acetate mixture as mobile phase. After completion of the reaction, the resulting solution was filtered and
the filtrate was left untroubled for slow evaporation of the
solvent. After 5 days, brown colored crystals suitable for
X-ray diffraction were obtained.
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets…
Carbonyldichlorido(1,1‑diethylthiourea)-bis(triphenylphos
phine)ruthenium(II) (1) The analytical and spectral data are
identical to the previously reported complex [25].
Carbonyldichlorido(1,1‑diethylthiourea)bis(triphenylarsine)ruthenium(II) (2, C
42H42As2Cl2N2O2RuS) Yield: 54%; color:
brown; IR (KBr): = 3380 (NH2), 1939 (C≡O), 829 (C=S)/
cm; 1H NMR (300.13 MHz, C
DCl3): δ = 8.21 (s, NH2),
7.21–7.80 (m, aromatic), 3.11 (q, J = 7.0 Hz, 2H, CH2),
3.02 (q, J = 7.0 Hz, 2H, CH2), 1.40 (t, J = 7.0 Hz, 3H, CH3),
1.37 (t, J = 7.0 Hz, 3H, CH3) ppm; 13C NMR (300.13 MHz,
C DCl 3): δ = 202.12 (C≡O), 172.14 (C=S), 126.64 (Ar
C), 119.24 (Ar C), 118.71 (Ar C), 112.41 (Ar C), 46.95
(CH2), 45.92 ( CH2), 14.32 ( CH3), 13.94 ( CH3) ppm; UV–
Vis (CHCl3): λmax (ε) = 238 (44,200), 266 (27,000), 339
(12,540), 443(5240) nm ( dm3/mol/cm); ESI-MS: m/z calcd.
944.68, found 909.22 ([M−Cl]+).
X‑ray structure determination
Crystals of complexes suitable for single crystal XRD were
grown from slow evaporation of methanol–chloroform solvent mixture (CCDC reference number 1584536). Suitable
single crystal of compounds with accurate dimensions was
mounted on a glass fiber containing epoxy cement. Crystal
data were collected on Gemini Ultra diffractometer. Structure solutions and refinements of the compounds were done
using the programs SHELXS-14 [40]. Refinement and all
further calculations were carried out using SHELXL. All
non-solvent heavy atoms were refined anisotropically. All
non-solvent hydrogen atoms were idealized using the standard SHELXL idealization methods [41]. When the nonhydrogen atoms will be refined by anisotropically, using
weighted full-matrix least squares on F2. Atomic scattering
factors were incorporated in the computer programs.
DNA‑binding studies
The binding interaction experiments of complex with CTDNA in double distilled water containing 95% Tris/NaCl
buffer (5 mM Tris–HCl/50 mM NaCl buffer, pH 7.2) were
carried out using a Fluoromax spectrofluorometer with a rectangular quartz cuvette of 1 cm path length. Stock solutions
of CT-DNA used in the studies not ever exceeded 5% DMSO
(v/v) in the final volume. A stock solution of CT-DNA was
stored at 277 K and used after no more than 4 days. Tris–HCl
buffer solution was used to base line correction. The excitation wavelength was fixed by the emission range and attuned
before measurements. The emissive titration experiments
were performed using a fixed concentration (25 µM) of test
compounds to which increments of the (0–10 µM) DNA
stock solution were added. The emission intensities were
1069
recorded for complexes in the range of 300–600 nm. Titrations were manually done by a micropipette for the addition
of CT-DNA and reference solution to eliminate the absorbance of CT-DNA itself. Further support for the relative binding property of complexes binding to DNA via intercalation
is given through emission quenching experiments. DNA was
pretreated with ethidium bromide (EB) for 30 min. Then
the test solutions were added to the mixture of EB-DNA,
and the change in the fluorescence intensity was measured.
The excitation and the emission wavelength were 510 nm
and 604 nm, respectively. EB was non-emissive in buffer
solution (pH 7.2) due to fluorescence quenching of the free
EB by solvent. In the fluorescence quenching spectra, the
reduction in emission intensity measured the binding mode
of complexes to CT-DNA.
Viscosity experiments were carried out using an Ubbelodhe viscometer at a constant temperature (30.0 ± 0.1 °C)
in a thermostat and the relative parameters were calculated
from the relation η = (t − to)/to, where t is the observed flow
time of DNA-containing solution and to is the flow time
of Tris–HCl/NaCl buffer alone. Data were presented as (η/
η0)1/3 vs binding ratio (r = [Compounds]/[DNA] = 0.0–0.1),
where η is the viscosity of CT-DNA in the presence of the
compound, and η0 is the viscosity of CT-DNA alone.
Protein binding studies
The excitation wavelength of BSA at 280 nm and the emission at 345 nm were monitored for the protein binding studies using fluorescence spectra recorded with synthesized
compounds. The excitation wavelength of BSA at 280 nm
and the quenching of the emission intensity of tryptophan
residues of BSA at 346 nm were monitored using the complexes as quenchers with increasing concentrations. The
excitation and emission slit widths (each 5 nm) remained
constant for all the experiments. A scan rate of 200 nm/min
was used. Samples were carefully degassed using pure nitrogen gas for 15 min. Stock solution of BSA was prepared in
50 µM phosphate buffer (pH 7.2) and stored in the dark at
4 °C for further use. Furthermore, the type of quenching
mechanism of complexes was determined from the UV–Vis
absorption spectra in the range of 200–600 nm.
In vitro anticancer activity:
3‑[4,5‑dimethylthiazol‑2‑yl]2,5‑diphenyltetrazolium
bromide (MTT) assay
The human cervical cancer (HeLa), human hepatocellular
carcinoma (HepG2) were obtained from National Centre
for Cell Science (NCCS), Pune and grown in Eagles Minimum Essential Medium containing 10% fetal bovine serum
(FBS). The cells were maintained at 37 °C, 95% air and
100% relative humidified atmosphere. The cytotoxicity of
13
1070
the investigated ruthenium(II) complex in comparison to cisplatin was determined using the MTT assay. The MTT colorimetric assay is based on the measurement of mitochondrial
enzyme succinate dehydrogenase activity, as an indication
of cell viability. MTT is a yellow water-soluble tetrazolium
salt. A mitochondrial enzyme in living cells, succinate dehydrogenase, cleaves the tetrazolium ring, converting the MTT
to an insoluble purple formazan. Therefore, the amount of
formazan produced is directly proportional to the number
of viable cells. After 48 h of incubation, 15 µM of MTT
(5 mg/cm3) in phosphate buffered saline (PBS) was added to
each well and incubated at 37 °C for 4 h. The medium with
MTT was then flicked off and the formed formazan crystals
were solubilized in 100 µM of DMSO and then measured
the absorbance at 570 nm using microplate reader. One hundred microliters per well of cell suspension were seeded into
96-well plates at plating density of 10,000 cells/well and
incubated to allow for cell attachment at 37 °C, 5% CO2,
95% air, and 100% relative humidity. After 24 h the cells
were treated with serial concentrations of the test samples.
They were initially dissolved in DMSO and an aliquot of
the sample solution was diluted to twice the desired final
maximum test concentration with serum free medium. Additional four serial dilutions were made to provide a total of
five sample concentrations. Aliquots of 100 mm3 of these
different sample dilutions were added to the appropriate
wells already containing 100 mm3 of medium, resulting in
the required final sample concentrations. Following sample
addition, the plates were incubated for an additional 48 h at
37 °C, 5% C
O2, 95% air, and 100% relative humidity. The
medium containing without samples was served as control
and triplicate was maintained for all concentrations. Nonlinear regression graph was plotted between % cell inhibition and log concentration and I C50 was determined using
Graph Pad Prism software.
Enzyme kinetic studies
The kinetics for the oxidation of catalytic oxidation of
3,5-ditertbutylcatechol (3,5-DTBC) and the hydrolysis
of 4-nitrophenyl phosphate (4-NPP) were monitored by
fluorescence spectra under pseudo first-order kinetic reaction. 100 equivalents of 3,5-DTBC and 40 equivalents
of 4-NPP in DMF ( 10−3 M) were added to 1 0−4 M solutions of ruthenium(II) complex under aerobic conditions.
Emissive intensity of the resultant reaction mixture was
plotted with respect to wavelength at a regular interval of
15 min using a fluorescence spectrophotometer in the range
410–700 nm. The dependence of the rate on substrate concentration and diverse kinetic parameters were obtained by
treatment of complexes with 3,5-DTBC and 4-NPP monitoring the increase in emission intensity at 435 and 485 nm,
13
P. Vijayan et al.
respectively (the peak corresponding to the band maxima),
as a function of time.
Acknowledgements Open access funding provided by TU Wien
(TUW). The authors thank UGC, India for financial assistance to
Department of Chemistry, Periyar University, Salem under SAP (no.
540/20/DRS-I/2016(SAP-I)).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativeco
mmons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Alderden RA, Hall MD, Hambley TW (2006) J Chem Educ
83:728
2. Kelland L (2007) Nat Rev Cancer 7:573
3. Breydo L, Uversky VN (2011) Metallomics 3:1163
4. Barry NPE, Sadler PJ (2013) Chem Commun 49:5106
5. Li VS, Choi D, Wang Z, Jimenez LS, Tang MS, Kohn H (1996) J
Am Chem Soc 18:2326
6. Zuber G, Quada JC, Hecht SM (1998) J Am Chem Soc 120:9368
7. Liu JG, Ye BH, Li H, Zhen QX, Ji LN, Fu YH (1999) J Inorg
Biochem 76:265
8. Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C
(2014) Chem Rev 114:815
9. Suess-Fink G (2010) Dalton Trans 39:1673
10. Vijayan P, Viswanathamurthi P, Sugumar P, Ponnuswamy MN,
Balakumaran MD, Kalaichelvan PT, Velmurugan K, Nandhakumar R, Butcher RJ (2015) Inorg Chem Front 2:620
11. Sanyal R, Guha A, Ghosh T, Mondal TK, Zangrando E, Das D
(2014) Inorg Chem 53:85
12. Mukherjee J, Mukherjee R (2002) Inorg Chim Acta 337:429
13. Neves A, Rossi LM, Bortoluzzi AJ, Szpoganicz B, Wiezbicki C,
Schwingel E (2002) Inorg Chem 41:1788
14. Gomathi A, Vijayan P, Viswanathamurthi P, Suresh S, Nandhakumar R, Hashimoto T (2017) J Coord Chem 70:1645
15. Nguyen HH, Abram U (2009) Eur J Inorg Chem 3179
16. Nguyen HH, Abram U (2007) Inorg Chem 46:5310
17. Castillo Gomez JD, Hagenbach A, Gerling-Driessen UIM, Koksch
B, Beindorff N, Brenner W, Abram U (2017) Dalton Trans
46:14602
18. Vijayan P, Viswanathamurthi P, Velmurugan K, Nandhakumar R,
Balakumaran MD, Malcki JG (2015) RSC Adv 5:103321
19. Barandov A, Abram U (2009) Inorg Chem 48:8072
20. Manikandan R, Anitha P, Prakash G, Vijayan P, Viswanathamurthi
P (2014) Polyhedron 81:619
21. Nguyen HH, Pham CT, Abram U (2015) Inorg Chem 54:5949
22. Maia PIS, Nguyen HH, Hagenbach A, Bergemann S, Gust R,
Deflon VM, Abram U (2013) Dalton Trans 42:5111
23. Sathiya Kamatchi T, Chitrapriya N, Lee H, Fronczek CF, Fronczek FR, Natarajan K (2012) Dalton Trans 41:2066
24. Manikandan R, Anitha P, Prakash G, Vijayan P, Viswanathamurthi
P, Butcher RJ, Malecki JG (2015) J Mol Catal A Chem 398:312
25. Vijayan P, Viswanathamurthi P, Sugumar P, Ponnuswamy MN,
Malecki JG, Velmurugan K, Nandhakumar R, Balakumaran MD,
Kalaichelvan PT (2017) Appl Organometal Chem 31:e3652
Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets…
26. Kalaivani P, Prabhakaran R, Poornima P, Dallemer F, Vijayalakshmi K, Vijaya Padma V, Natarajan K (2012) Organometallics
31:8323
27. Paitandi RP, Gupta RK, Singh RS, Sharma G, Koch B, Pandey
(2014) Eur J Med Chem 84:17
28. Jaividhya P, Dhivya R, Akbarsha MA, Palaniandavar M (2012) J
Inorg Biochem 114:94
29. Rajarajeswari C, Loganathan R, Palaniandavar M, Suresh E, Riyasdeen A, Akbarshae MA (2013) Dalton Trans 42:8347
30. Almes FJM, Porschke D (1993) Biochemistry 32:4246
31. Baron ESG, DeMeio RH, Klemperer F (1936) J Biol Chem
112:625
32. Liu YJ, Liang JH, Li ZZ, Yao JH, Huang HL (2011) J Organomet
Chem 696:2728
33. Rajendiran V, Karthik R, Palaniandavar M, Evans HS, Periasamay
VS, Akbarsha MA, Srinag BS, Krishnamurthy H (2007) Inorg
Chem 46:8208
1071
34. Yu Q, Liu Y, Zhang J, Yang F, Sun D, Liu D, Zhou Y, Liu J (2013)
Metallomics 5:222
35. Lackowicz JR, Weber G (1973) Biochem J 12:4161
36. Chyn JP, Urbach FL (1991) Inorg Chim Acta 189:157
37. Vogel AI (1989) Text book of practical organic chemistry. Longman, London
38. Ogiwara Y, Miyake M, Kochi T, Kakiuchi F (2017) Organometallics 36:159
39. Vijayan P, Viswanathamurthi P, Silambarasan V, Velmurugan D,
Velmurugan K, Nandhakumar R, Butcher RJ, Silambarasan T,
Dhandapani R (2014) J Organomet Chem 768:163
40. SMART & SAINT (1998) Software reference manuals, version
5.0. Bruker AXS Inc, Madison
41. Sheldrick GM (1997) SHELXL97. Program for Crystal Structure
Refinement. University of Gottingen, Gottingen
13